By inhibiting or modulating the activity of SLC16A3, it may be possible to disrupt lactate export, alter the tumor microenvironment, and potentially enhance the effectiveness of other cancer treatments [26, 35, 36]. Here, SLC16A3 is linked to neoplasm.